| Autor: |
Salma Al Bahrani, Ali Albarrak, Othman Ali Alghamdi, Mesfer Abdullah Alghamdi, Fatimah H. Hakami, Asmaa K. Al Abaadi, Sausan A. Alkhrashi, Mansour Y. Alghamdi, Meshael M. Almershad, Mansour Moklif Alenazi, Mohamed Hany El Gezery, Arulanantham Zechariah Jebakumar, Jaffar A. Al-Tawfiq |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
International Journal of Infectious Diseases, Vol 110, Iss , Pp 359-362 (2021) |
| Druh dokumentu: |
article |
| ISSN: |
1201-9712 |
| DOI: |
10.1016/j.ijid.2021.07.052 |
| Popis: |
Introduction: The Kingdom of Saudi Arabia was one of the first countries to implement a COVID-19 vaccination program. This study estimated the safety and reactogenicity of the ChAdOx1-S vaccine after the first dose administered to adults. Methods: This cross-sectional study included 1592 randomly selected vaccinees from April to May 2021. A questionnaire was delivered to the vaccinees via phone calls 7 and 21 days after the first vaccine dose. Results: Of the 1592 vaccinees who had the first dose, the mean age was 37.4 (± 9.6) years and 81% were males. Of all the vaccinees, 553 (34.7%) reported an adverse reaction on the first telephone call. The most common symptoms were: pain at the site of injection (485, 30.5%), musculoskeletal symptoms (438, 27.5%), skin rash (307, 19.2%), gastrointestinal symptoms (379, 23.8%) and fever (498, 31.3%). Men were more likely to report fever (76.9% vs. 23.1%; P = 0.005), skin rash (81.1% vs. 18.9%, P = 0.005) and pain at the injection site (77.3% vs. 22.7%, P < 0.0001). Post-vaccine COVID-19 infection was 0.5% and there were no hospitalizations. Conclusion: This study observed no major side effects of the ChAdOx1-S vaccine and no reported breakthrough infection during the observation period. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
